Medicus Pharma (MDCX) Research & Development (2024 - 2025)
Medicus Pharma (MDCX) reported Research & Development of $3.6 million for Q4 2025, up 162.76% on a YoY basis from $1.4 million in Q4 2024, and up 112.9% quarter-over-quarter from $1.7 million in Q3 2025.
Medicus Pharma (MDCX) Research & Development (2024 - 2025) Analysis & Trends
Medicus Pharma has reported Research & Development for 2 years, with the latest figure at $3.6 million in Q4 2025.
- For the quarter ending Q4 2025, Research & Development rose 162.76% year-over-year to $3.6 million; the trailing twelve-month figure through Dec 2025 stood at $8.7 million (up 194.15% YoY), and the FY2025 full-year result was $8.7 million, up 147.11% from the prior year.
- Research & Development for Q4 2025 stood at $3.6 million, up from $1.7 million in the prior quarter.
- The five-year high for Research & Development was $3.6 million in Q4 2025, with the low at $321377.0 in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | -2.28 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 3.51 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 3.53 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 2.47 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 12.59 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 1.72 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 1.37 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 2.49 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 2.65 Bn |
| 10 | Medicus Pharma | 6.05 Mn | 6.15 Mn | - | 3.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.59 Mn |
| Sep 30, 2025 | 1.68 Mn |
| Jun 30, 2025 | 1.44 Mn |
| Mar 31, 2025 | 2.01 Mn |
| Dec 31, 2024 | 1.37 Mn |
| Jun 30, 2024 | 1.28 Mn |
| Mar 31, 2024 | 321,377.00 |